top of page
Expanded Performance Comparison of the Oncuria 10-Plex Bladder Cancer Urine Assay Using Three Different Luminex xMAP Instruments
Date: July 10, 2025 PMID: PMC12294033 Category: N/A Authors: Sunao Tanaka, Takuto Shimizu, Ian Pagano, Wayne Hogrefe, Sherry Dunbar, Charles J Rosser, Hideki Furuya Abstract: 40722499 Background/Objectives : The clinically validated multiplex Oncuria bladder cancer (BC) assay quickly and noninvasively identifies disease risk and tracks treatment success by simultaneously profiling 10 protein biomarkers in voided urine samples. Oncuria uses paramagnetic bead-based fluorescence
bgtaylor1
Nov 11, 20252 min read
BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization
Date: August 22, 2025 PMID: PMC12240483 Category: N/A Authors: Yixuan Zhao, Rachael Liu, Jianchang Lin, Ying Yuan Abstract: 40626646 One common approach for dose optimization is a two-stage design, which initially conducts dose escalation to identify the maximum tolerated dose, followed by a randomization stage where patients are assigned to two or more doses to further assess and compare their risk-benefit profiles to identify the optimal dose. A limitation of this approach
bgtaylor1
Nov 11, 20252 min read
Pancreatic islet β-cell subtypes are derived from biochemically-distinct and nutritionally-regulated islet progenitors
Date: July 1, 2025 PMID: PMC12217943 Category: N/A Authors: Monica E Brown, Verda E Miranda, Simone Nevills, Ruiying Hu, Prasanna K Dadi, Alan J Simmons, Yanwen Xu, Yilin Yang, Mahircan Yagan, Sadia Najam, Leesa L Sampson, Mark A Magnuson, David A Jacobson, Ken S Lau, Emily Hodges, Guoqiang Gu Abstract: 40593675 Endocrine islet β cells comprise heterogenous subtypes with different gene expression and function levels. Here we study when/how this heterogeneity is induced and ho
bgtaylor1
Nov 11, 20252 min read
bottom of page